Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics is a biopharmaceutical company with a positive outlook due to its potential for high growth and large upside opportunities in the ~$billion breast cancer market. Despite the risks associated with clinical trials, the company's recent filing of its IND application for (Z)-Endoxifen in Metastatic Breast Cancer and its efforts to expand its indications beyond metastatic breast cancer demonstrate its strong progress and potential for success in the future. Additionally, the company's current valuation is attractive, and it has one main therapeutic drug candidate in development, making it a promising investment opportunity.

Bears say

Atossa Therapeutics is facing several fundamental risks, including potential balance sheet and liquidity issues, the possibility of product candidates failing to meet safety and efficacy standards in clinical trials, and difficulties in gaining regulatory approvals and commercializing products due to competition and changing macroeconomic factors. The recent appointment of Mark Daniel as Chief Financial Officer may bring some positive changes, however, with his strong background in finance and experience in the life science industry.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.